Market Cap 9.54M
Revenue (ttm) 0.00
Net Income (ttm) -13.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 106,500
Avg Vol 83,122
Day's Range N/A - N/A
Shares Out 6.16M
Stochastic %K 29%
Beta 0.51
Analysts Strong Sell
Price Target $17.50

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 77 331 0156
Address:
Building 7, Kiryat Atidim, Tel Aviv, Israel
Rolex53
Rolex53 Feb. 4 at 4:41 AM
0 · Reply
Rolex53
Rolex53 Feb. 4 at 3:25 AM
$CMMB Compared to rest of the market we are at better shape now. A good news can move it up to $10. Obviously if there is no runner on the day of the news then why not $20...$30 as it is low float or nano float now.
0 · Reply
dom3
dom3 Feb. 2 at 3:13 PM
$CMMB Volume remains feeble but for the second day running the stock wants to hold above 1.50 which at least is a decent sign. Need the company to throw us a lifeline.
0 · Reply
Tigerfromasia
Tigerfromasia Feb. 2 at 12:47 PM
$CMMB Announce the goddamn partnership already
0 · Reply
DLTT4489
DLTT4489 Feb. 1 at 2:17 PM
$CMMB bloooooody weeeek ahead bulllllsss, keep buying 🤪🤑🤪🤑🤪🤑🤪🤑💰
1 · Reply
DLTT4489
DLTT4489 Jan. 31 at 5:58 PM
$CMMB Morgan Stanley🤣🤣🤣
0 · Reply
DLTT4489
DLTT4489 Jan. 30 at 9:27 PM
$CMMB volume is insane 😅😅😅😅
0 · Reply
dom3
dom3 Jan. 30 at 7:31 PM
$CMMB Has reached a key level on the downside. Feels like it has bottomed but it has done this before. Needs to break 1.70 on volume to get some momentum.
1 · Reply
Zdxss1
Zdxss1 Jan. 30 at 2:43 PM
$CMMB All the clinical trials the company conducted were not the ultimate goal, but rather a means to demonstrate that CCL24 is a key biomarker in chronic inflammation and fibrosis, and that CM-101 can significantly reduce it. These studies also showed that CCL24 is involved in multiple inflammatory pathways across the body. Given this evidence, it is likely that the company will pursue a faster and more valuable path: expedited approval for the treatment of chronic inflammation, now that the role of CCL24 has been scientifically, medically, and clinically validated.
0 · Reply
JoeShmoDoe
JoeShmoDoe Jan. 29 at 11:34 PM
$CMMB what a joke here!
0 · Reply
Latest News on CMMB
Chemomab Announces New Medical and Clinical Appointments

Apr 15, 2025, 8:00 AM EDT - 10 months ago

Chemomab Announces New Medical and Clinical Appointments


Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:38 AM EDT - 1 year ago

Chemomab Therapeutics Announces $10 Million Private Placement


Rolex53
Rolex53 Feb. 4 at 4:41 AM
0 · Reply
Rolex53
Rolex53 Feb. 4 at 3:25 AM
$CMMB Compared to rest of the market we are at better shape now. A good news can move it up to $10. Obviously if there is no runner on the day of the news then why not $20...$30 as it is low float or nano float now.
0 · Reply
dom3
dom3 Feb. 2 at 3:13 PM
$CMMB Volume remains feeble but for the second day running the stock wants to hold above 1.50 which at least is a decent sign. Need the company to throw us a lifeline.
0 · Reply
Tigerfromasia
Tigerfromasia Feb. 2 at 12:47 PM
$CMMB Announce the goddamn partnership already
0 · Reply
DLTT4489
DLTT4489 Feb. 1 at 2:17 PM
$CMMB bloooooody weeeek ahead bulllllsss, keep buying 🤪🤑🤪🤑🤪🤑🤪🤑💰
1 · Reply
DLTT4489
DLTT4489 Jan. 31 at 5:58 PM
$CMMB Morgan Stanley🤣🤣🤣
0 · Reply
DLTT4489
DLTT4489 Jan. 30 at 9:27 PM
$CMMB volume is insane 😅😅😅😅
0 · Reply
dom3
dom3 Jan. 30 at 7:31 PM
$CMMB Has reached a key level on the downside. Feels like it has bottomed but it has done this before. Needs to break 1.70 on volume to get some momentum.
1 · Reply
Zdxss1
Zdxss1 Jan. 30 at 2:43 PM
$CMMB All the clinical trials the company conducted were not the ultimate goal, but rather a means to demonstrate that CCL24 is a key biomarker in chronic inflammation and fibrosis, and that CM-101 can significantly reduce it. These studies also showed that CCL24 is involved in multiple inflammatory pathways across the body. Given this evidence, it is likely that the company will pursue a faster and more valuable path: expedited approval for the treatment of chronic inflammation, now that the role of CCL24 has been scientifically, medically, and clinically validated.
0 · Reply
JoeShmoDoe
JoeShmoDoe Jan. 29 at 11:34 PM
$CMMB what a joke here!
0 · Reply
DLTT4489
DLTT4489 Jan. 29 at 4:26 PM
$CMMB bleed bleed 😅😅😅
0 · Reply
DLTT4489
DLTT4489 Jan. 28 at 7:55 PM
0 · Reply
Digitalization2026
Digitalization2026 Jan. 28 at 4:59 PM
$AKAN $CITR $CMMB $USAS $FEED $AKAN Update 📈 | Grinding Toward $1.75 $AKAN is continuing to push higher, working its way toward the $1.75 area as buyers defend higher lows. In a small-float name, these steady advances matter more than flashy candles. What to watch 👀 • Volume expansion near $1.75 • Ability to hold above $1.60–$1.65 • Clean break of $1.75 → opens a $2 test • Any filings or telecom-related news Why it’s still on radar: AKAN has pivoted into telecom infrastructure with real tower and fiber assets. This is a structure + catalyst story, not just hype. Upcoming catalysts 🔎 • Telecom leasing or fiber monetization updates • Strategic partnerships • Capital structure clarity via SEC filings Speculative targets 🎯 • Base: $2$3 • Momentum: $6$10 🚀 • Strong rerate: $15$25+ 🔥 Let price and volume do the talking.
0 · Reply
Snptrader
Snptrader Jan. 28 at 2:19 PM
$CMMB Sent a formal shareholder letter to CMMB management/Board yesterday. Clear message: no more reverse splits and dilution. At this point, it’s not value-maximizing — it’s value destruction. Called for the Board to engage an independent banker to evaluate strategic alternatives, including a sale of the company or monetization of PSC and/or SSC rights instead of diluting shareholders again. Also unacceptable that it’s a month into 2026 with no Phase 3 NCT number — suggests FDA/EMA alignment isn’t done despite prior guidance. That’s a Board-level oversight issue. Other shareholders should speak up. Silence enables this.
2 · Reply
Zdxss1
Zdxss1 Jan. 28 at 10:49 AM
$CMMB What I haven't seen clearly stated—neither by financial analysts nor in medical reports—is that the core of the CC-101 story isn't about "curing a disease" as much as it is about "reducing a harmful biological target." The real value of CC-101 lies in reducing CCL24, the primary driver of fibrosis and chronic inflammation. It reminds me of statins. 🤔 Does that make sense?
3 · Reply
shreyvakil
shreyvakil Jan. 27 at 10:30 PM
$CMMB awesome moving forward progress!
1 · Reply
dom3
dom3 Jan. 27 at 3:10 PM
$CMMB Day two with small caps down and cmmb holding above the 1.70 level. Not rejoicing but offering some hope. Cant have DLTT spitting in our face everyday. Although i thought you predicted 1.20 by the end of the month DLTT.
0 · Reply
DLTT4489
DLTT4489 Jan. 27 at 12:29 AM
$CMMB losers covering each other, how idiot are you.
1 · Reply
dom3
dom3 Jan. 26 at 7:43 PM
$CMMB Shreyvakil; We are closer to something. The volume is mystifying. Still too many sellers for a stock that is massively oversold and can literally soar in an instant on a partnership deal. Would love to see it up even then slowly climb for the remainder of the day as opposed to a green opening and red close.
0 · Reply
shreyvakil
shreyvakil Jan. 26 at 5:14 PM
$CMMB all it says is we are getting closer
0 · Reply
dom3
dom3 Jan. 26 at 4:53 PM
$CMMB Strange trading today on cmmb, both bullish and bearish. Strong buying at the open and then fade away.
0 · Reply
dom3
dom3 Jan. 26 at 4:52 PM
0 · Reply